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The human genome contains a category of repeat sequences
referred to as human endogenous retroviruses (HERVs), which
occupies up to 8% of the nucleotide sequences. HERVs have
mutated and/or fragmented provirus structures of once-infectious
retroviruses, and have lost their ability to replicate or transpose.
Nonetheless, proteins encoded by different types of HERVs still
show biological activities in various modes, and most of the
regulatory regions termed “long terminal repeats” (LTRs) pre-
serve the function as a promoter–enhancer region. Release from
epigenetic silencing and activation of transcription factors can
cause “awakening” of HERVs and LTRs involved in tumorigene-
sis, self-defense, and tissue development. This research topic is a
compilation of unique reviews on HERVs and mouse endogenous
retroviruses (ERVs) and original articles indicating new insights
into HERVs.
HERV-K(HML-2) AS A FOSSIL VIRUS AND A FUNCTIONAL
ELEMENT
Human endogenous retroviruses-K(HML-2), the most recently
integrated HERV family, preserve a nearly complete retrovirus
structure, and has been an interesting subject in virology, genome
biology, oncology, and pathology of autoimmune diseases. In the
comprehensive Review Article (1), Hohn et al. outlined current
knowledge on HERV-K(HML-2) including the topics of endoge-
nization, genes-and-proteins, evolution, and tissue development.
Moreover, the activation of HERV-K(HML-2) in diseases and
the possibility of HERV-K-mediated oncogenesis were extensively
discussed.
EXPRESSION OF HERV-K IN CANCERS
Agoni et al. contributed an Original Research Article (2) on the
locus-specific analysis of HERV-K(HML-2) expression in prostate
cancer cell lines. In addition to the previously known cancer types,
melanoma, breast cancer, etc., prostate cancer was also found to
express HERV-K and the LTR. Activation of specific HERV-K
loci and an abundance of solo LTR-containing transcripts were
described. As these authors mentioned, with deeper examination,
this approach could possibly lead to determination of a clinical
significance of HERV expression.
HERV AS THE TARGET OF CANCER IMMUNOTHERAPY
Tumor cells express extra genes, such as HERVs, that are repressed
in normal cells. If a HERV-derived protein is tumor-specific, it
could be a useful marker in cancer diagnosis and therapy. As
described by Cherkasova et al. (3), this hypothesis was proven by
identification of the novel HERV-E-derived peptides of renal cell
carcinomas as the target antigens in successful hematopoietic stem
cell transplantation therapy. The authors discussed the mecha-
nism of cancer-specific HERV expression as well as immunological
responses to various types of HERV proteins.
GREAT CONFUSION CAUSED BY A RECOMBINANT MOUSE
ERV IN CANCER RESEARCH
In contrast to HERVs, ERVs of mouse laboratory strains currently
remain active. Mice producing infectious viruses have provided
interesting animal models for tumor biology in the past. Ironi-
cally, the nature of mouse ERVs has been recently“rediscovered” in
human prostate cancer cells through contamination of a recombi-
nant ERV termed xenotropic murine leukemia virus-related virus
(XMRV). The Mini Review by Hempel et al. (4) covered the entire
story, and raised alerts of the threat of XMRV-like virus spreading
in laboratories, and for the virus-caused phenotypic changes of
xenotransplanted cancer cells.
EPIGENETIC CHANGES OF RETROELEMENTS IN CANCERS
DNA hypomethylation is thought to be a major and common
cause of the activation of retrotransposons in cancer development.
Kreimer et al. (5) studied methylation status and expression of
three retroelements, LINE-1, HERV-K, and AluY, in bladder can-
cer tissues and cell lines. They detected a considerable correlation
between hypomethylation and transcription of LINE-1. Retroele-
ments may undergo epigenetic control in different modes based
on the tissues, subclasses, and chromosomal loci.
HERVs AS NON-MOVABLE TRANSPOSONS ASSOCIATED
WITH HUMAN DISEASES
Human endogenous retroviruses and HERV-derived LTRs, with
mammalian apparent LTR-retrotransposons (MaLRs), compose
the subclass of LTR-retrotransposons. Recent evidence indicated
association of these elements with pathogenesis and a beneficial
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role in tumor therapy. Katoh and Kurata (6) summarized the
influences of LTR-retrotransposons on human health and diseases,
compared with presently active non-LTR-retrotransposons.
IMMUNE REGULATION BYMtv, THE ENDOGENOUS FORM OF
MOUSE MAMMARY TUMOR VIRUS
Mouse mammary tumor virus and Mtv have attracted HERV sci-
entists because of the structural and functional similarity between
MMTV/Mtv and certain HERVs, and the presence of superantigen
(Sag) in MMTV/Mtv and HERV-K18. Holt et al. (7) contributed
a fresh Review focusing on Mtv, in which the impacts of this
element on immune responses, infectious diseases, and tumor
development were discussed in great detail.
MOUSE ENDOGENOUS RETROVIRUS MuERV-L/MERVL IN
STEM CELLS
Studies on epigenetic regulation of ERVs in mouse stem cells are,
although indirectly, meaningful for elucidation of the status of
HERVs in development and carcinogenesis. Schoorlemmer et al.
(8) explained silencing of MERVL, a distinct type of ERV expressed
at the two-cell stage after fertilization,by histone modification with
orchestration of multiple proteins. They offered an interesting
hypothesis of MERVL LTR-mediated regulation of neighboring
genes relevant to the stem cell potency.
All these articles which came from diverse backgrounds illus-
trated HERVs/ERVs from the basics to the frontlines, providing
new perspectives. There was a great deal of discussion concerning
the epigenetic control of HERVs/ERVs in embryonic development
and tumorigenesis. HERVs and LTRs are emerging as genome
inhabitants associated with human pathogenesis.
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